TERN-601

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Overweight or Obesity

Conditions

Overweight or Obesity

Trial Timeline

Mar 7, 2025 → Sep 19, 2025

About TERN-601

TERN-601 is a phase 2 stage product being developed by Terns Pharmaceuticals for Overweight or Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT06854952. Target conditions include Overweight or Obesity.

What happened to similar drugs?

1 of 20 similar drugs in Overweight or Obesity were approved

Approved (1) Terminated (0) Active (19)
AripiprazoleBristol Myers SquibbApproved
🔄Eloralintide + PlaceboEli LillyPhase 3
🔄Eloralintide + PlaceboEli LillyPhase 3
🔄Tirzepatide + PlaceboEli LillyPhase 3
🔄Tirzepatide + PlaceboEli LillyPhase 3
🔄Semaglutide + Semaglutide PlaceboNovo NordiskPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06854952Phase 2Completed

Competing Products

20 competing products in Overweight or Obesity

See all competitors